Study identifier:D6150C00001
ClinicalTrials.gov identifier:NCT02583165
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors
Advanced Solid Tumors
Phase 1
No
-
All
40
Interventional
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: Safety/Efficacy
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jun 2020 by MedImmune, LLC
MedImmune, LLC
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Monotherapy arm MEDI1873 | Biological/Vaccine: MEDI1873 Subjects will receive MEDI1873 by intravenous administration |